Mediolanum Farmaceutici SRL
http://www.mediolanum-farma.it/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mediolanum Farmaceutici SRL
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Deals Shaping the Medical Industry, December 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
DEALS ROUND-UP: M&A and partnering 1-28 December
As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.
Deals Of The Week: Baxter/Gambro, Optimer/AstraZeneca, Ironwood/Protagonist
Three rapid-fire clinical setbacks scuttled a planned merger between BioCryst and Presidio that would have created a new competitor in the hepatitis C space. Now, BioCryst is retrenching with a staff cut and narrower R&D focus.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice